Ankylosing Spondylitis Market Transformation Driven by Biologics & Biosimilars

Ankylosing Spondylitis Market Size, Growth and Value Chain Analysis with Regional Insights

The global ankylosing spondylitis market size is calculated at USD 6.7 billion in 2025, grew to USD 7.09 billion in 2026, and is projected to reach around USD 11.83 billion by 2035. The market is expanding at a CAGR of 5.85% between 2026 and 2035.

The ankylosing spondylitis market is primarily driven by the increasing research activities and the rising prevalence of autoimmune disorders. Innovative biologics are developed for the prevention, diagnosis, and treatment of ankylosing spondylitis (AS). Government bodies provide funding for research and manufacturing of pharmaceuticals. Artificial intelligence (AI) revolutionizes the market by streamlining the diagnosis and treatment of AS.

Key Takeaways

• Ankylosing spondylitis sector pushed the market to USD 6.7 billion by 2025.
• Long-term projections show USD 11.83 billion valuation by 2035.
• Growth is expected at a steady CAGR of 5.85% in between 2026 to 2035.
• North America held a major revenue share of approximately 40% in the market in 2024.
• Asia-Pacific is expected to witness the fastest growth with a CAGR of approximately 12% during the predicted timeframe.
• By drug class, the TNF inhibitors segment dominated the ankylosing spondylitis market with a share of approximately 45% in 2024.
• By drug class, the IL-17 inhibitors segment is expected to grow with the highest CAGR of approximately 12% in the market during the studied years.
• By route of administration, the subcutaneous segment held a dominant revenue share of approximately 50% in the market in 2024.
• By route of administration, the oral segment is expected to witness the fastest growth with a CAGR of approximately 13% in the market over the forecast period.
• By disease stage, the moderate ankylosing spondylitis segment contributed the biggest revenue share of approximately 48% in the market in 2024.
• By disease stage, the early-stage ankylosing spondylitis segment is expected to grow at the fastest CAGR of approximately 10% in the ankylosing spondylitis market during the forecast period.
• By diagnostic method, the MRI segment held the largest revenue share of approximately 40% in the market in 2024.
• By diagnostic method, the digital spine monitoring tools segment is expected to show the fastest growth with a CAGR of approximately 13% over the forecast period.
• By end-user, the hospitals segment accounted for the highest revenue share of approximately 45% in the market in 2024.
• By end-user, the specialty rheumatology clinics segment is expected to expand rapidly with a CAGR of approximately 12% in the market in the coming years.

Key Indicators and Highlights

Unlocking the Spine: Innovations Reshaping the AS Landscape

The ankylosing spondylitis market is experiencing robust growth, driven by the increasing prevalence of spondyloarthropathies, early diagnosis initiatives, rising adoption of biologics, and the growing demand for targeted immunotherapies. It includes pharmaceuticals, biologics, biosimilars, diagnostics, monitoring tools, and supportive care services used for the treatment and long-term management of AS, a chronic, progressive inflammatory disease primarily affecting the axial skeleton. The market covers TNF inhibitors, IL-17 inhibitors, JAK inhibitors, NSAIDs, DMARDs, physical therapy solutions, diagnostic imaging, and disease monitoring technologies.

Ankylosing Spondylitis Market Outlook

• Industry Growth Overview: The market is expected to grow rapidly, driven by the increasing development of personalized medicines and innovative diagnostics. Advances in cell therapy, particularly mesenchymal stem cells (MSCs) and CAR-T cell therapy, demonstrate promise in addressing limitations.
• Startup Ecosystem: The startup ecosystem is maturing, driven by significant growth in venture capital investments and the rising adoption of advanced technologies. Hillstar Bio, Trinity Biotech, and NeoDx Biotech Labs are some startups involved in the treatment and diagnosis of AS.
• Major Investors: Several government and private organizations provide funding to pharma and biotech companies, assisting in the development of innovative immunotherapies, stem cells, and in vitro diagnostics. Funding also allows healthcare organizations to adopt advanced tools for AS diagnosis and treatment.

Smart Spine Solutions: AI Transforming the Ankylosing Spondylitis Market

AI and machine learning (ML) algorithms transform the prevention, diagnosis, and treatment of AS. They are embedded in diagnostic tools, such as X-ray and MRI, to analyze imaging data, increasing the accuracy of AS diagnosis. They also enable healthcare professionals to identify novel biomarkers involved in disease progression. Furthermore, they can also suggest appropriate treatment regimens based on patients’ conditions, as well as predict treatment responses to aid patient-specific treatment planning.

Segmental Insights

Drug Class Insights

Which Drug Class Segment Dominated the Ankylosing Spondylitis Market?

TNF Inhibitors

The TNF inhibitors segment held a dominant position in the market with a share of approximately 45% in 2024, driven by the growing need for targeted therapies and the demand for symptom relief. THF inhibitors, such as etanercept, adalimumab, and infliximab, suppress the immune system by targeting TNF, thereby reducing inflammation in the joints. As TNF inhibitors directly act on the immune system, they treat a disease from its root cause. They prevent structural damage to the bones and enhance the overall well-being of patients.

IL-17 Inhibitors

The IL-17 inhibitors segment is expected to grow at the fastest CAGR of approximately 12% in the ankylosing spondylitis market during the forecast period. IL-17 inhibitors, such as secukinumab and ixekizumab, block the IL-17A pathway, reducing inflammation in arthritis. Several studies have demonstrated the safety and effectiveness of IL-17 inhibitors. They have also found that IL-17 inhibitors produce favorable response rates compared to other therapeutics.

Emerging Biologic Therapies

The emerging biologic therapies segment is expected to grow in the coming years, due to growing research activities and advancements in genomic technologies. As ankylosing spondylitis is also caused by genetic mutations, novel cell and gene therapies are under development. Researchers have shifted focus to the development of personalized medicines and determining their safety profile.

Route of Administration Insights

Why Did the Subcutaneous Segment Dominate the Ankylosing Spondylitis Market?

Subcutaneous

The subcutaneous segment contributed the biggest revenue share of approximately 50% in the market in 2024, due to the development of advanced subcutaneous (s.c.) delivery devices and the administration of drugs directly under the skin. Usually, IL-17 inhibitors (secukinumab) are administered through the s.c. Route. Advanced devices enable patients to self-administer the drug, eliminating the need for skilled professionals. The s.c. Route causes less discomfort and is easier to administer, enhancing patient compliance.

Oral

The oral segment is expected to grow with the highest CAGR of approximately 13% in the ankylosing spondylitis market during the studied years. The oral route is more convenient and reduces adverse effects related to injections. They can be modified to enable sustained release and immediate release based on patients’ conditions. Tofacitinib and Upadacitinib are administered through the oral route for the treatment of AS.

Intravenous

The intravenous segment is expected to grow significantly, due to high bioavailability and faster onset of action. Drugs administered through the intravenous (i.v.) route have shown clinical significance and improvements in signs and symptoms. The i.v. The route eliminates the first-pass metabolism pathway and administers the drug directly into the bloodstream. It transports the drug to different body parts.

Disease Stage Insights

How the Moderate Ankylosing Spondylitis Segment Dominated the Ankylosing Spondylitis Market?

The moderate ankylosing spondylitis segment held the largest revenue share of approximately 48% in the market in 2024, due to the faster progression of the disease. During moderate AS, the pain may spread up the spine to the neck. The symptoms of moderate AS are more visible compared to the early stage of AS, allowing healthcare professionals to monitor visible signs of the disease and make effective clinical decisions.

Early-Stage Ankylosing Spondylitis

The early-stage ankylosing spondylitis segment is expected to expand rapidly with a CAGR of approximately 10% in the ankylosing spondylitis market in the coming years. People are becoming more aware of screening and early diagnosis of early-stage AS. Early-stage AS may involve frequent stiffness and pain in the lower back and buttocks. It is usually treated through physical therapy and medications.

Severe/Advanced Ankylosing Spondylitis

The severe/advanced ankylosing spondylitis segment is expected to show lucrative growth. Severe stage results in progressive back stiffness, impaired posture, and breathing difficulties. It is difficult to treat with medications and physical therapy alone. Some patients may need joint repair or replacement surgeries when severe joint damage is present. Treatment relieves stiffness and pain, maintains spinal motion, and prevents further complications.

Diagnostic Method Insights

What Made MRI the Dominant Segment in the Ankylosing Spondylitis Market?

MRI

The MRI segment accounted for the highest revenue share of approximately 40% in the market in 2024, due to the high accuracy of MRI to detect early changes of spondylitis. MRI is more sensitive than CT or plain radiography in detecting inflammatory changes. AI and ML are leveraged in MRI to enhance the accuracy and precision of diagnosis. They also assist healthcare professionals in analyzing imaging data.

Digital Spine Monitoring Tools

The digital spine monitoring tools segment is expected to witness the fastest growth with a CAGR of approximately 13% in the ankylosing spondylitis market over the forecast period. Advances in mobile technologies, electric health, and smartphone applications are being developed to diagnose AS. Smartphone apps and wearable sensors are used for remote monitoring, eliminating the need for visiting healthcare organizations. This also enables healthcare professionals to continuously monitor a patient, providing personalized treatment.

Blood Biomarkers

The blood biomarkers segment is expected to grow at a notable CAGR due to simplicity in diagnostic tests and high affordability. Patients suffering from AS have AS-specific mRNA biomarkers in their whole blood. Numerous in vitro and point-of-care diagnostics are developed to evaluate whole blood and quantify biomarkers from the blood. Ongoing efforts are made to identify novel biomarkers that are involved in disease progression.

End-User Insights

Which End-User Segment Led the Ankylosing Spondylitis Market?

Hospitals

The hospitals segment led the market with a share of approximately 45% in the market in 2024, due to favorable infrastructure and the presence of skilled professionals. Hospitals have professionals from various disciplines, providing multidisciplinary expertise to patients. Patients prefer visiting a hospital for AS treatment due to favorable reimbursement policies. Hospitals are involved in clinical trials that benefit patients with innovative treatment before market approval.

Specialty Rheumatology Clinics

The specialty rheumatology clinics segment is expected to show the fastest growth with a CAGR of approximately 12% over the forecast period. Specialty clinics possess skilled professionals to provide personalized treatment and care. They also adopt specialized equipment that focuses on rheumatology for diagnosis and medication, as well as physical medicine and rehabilitation for non-surgical management.

Ambulatory Care Centers

The ambulatory care centers segment is expected to grow in the upcoming years. Ambulatory care centers provide outpatient services for AS. They have skilled professionals and suitable infrastructure for conducting minor or minimally invasive surgeries. Ambulatory care centers focus on pain management, maintaining mobility, and preventing spinal stiffness, enabling patient comfort and well-being.

Regional Analysis

Which Factors Govern the Ankylosing Spondylitis Market in North America?

North America dominated the global market with a share of approximately 40% in 2024. The availability of state-of-the-art research and development facilities, a robust healthcare infrastructure, and the presence of key players are factors that govern market growth in North America. Countries like the U.S. and Canada are at the forefront of conducting research and clinical trials for innovative biologics. Government organizations launch initiatives to promote screening and early diagnosis of AS.

Robust Clinical Trial Infrastructure Dominated the U.S.

It is estimated that around 0.2-0.5% of the total population in the U.S. suffers from AS. There are over 658 active rheumatology physician group practices in the U.S., providing AS treatment. The U.S. has a well-established clinical trial infrastructure, accounting for 91 clinical trials as of November 2025. Of these, 18 trials are active.

How is Asia-Pacific Growing in the Ankylosing Spondylitis Market?

Asia-Pacific is expected to host the fastest-growing market with a CAGR of approximately 12% in the coming years. The increasing prevalence of ankylosing spondylitis, the expanding middle-class population, and sedentary lifestyles boost the market. The growing research and development activities and the increasing adoption of advanced technologies propel market growth. The burgeoning healthcare sector, along with the rising number of biotech startups, contributes to market growth.

Increasing AS Prevalence Fuels China’s Growth

The prevalence rate of AS in China is approximately 0.29% with a male-to-female ratio of approximately 3:1, and most cases occur in the adolescent period. The nation focuses on bridging the gap between the number of rheumatologists and patients. Currently, there are 12,189 rheumatology and immunology specialists in China for over 200 million patients.

Will Europe Grow in the Ankylosing Spondylitis Market?

Europe is considered to be a significantly growing area, due to favorable government support and growing demand for personalized medicines. The European Medicines Agency (EMA) regulates the approval of AS diagnostics and therapeutics. Healthcare organizations in European nations have advanced infrastructure for providing personalized care. The rapidly expanding biopharmaceutical sector, along with increasing investments by government and private bodies, fosters market growth.

Government Funding to Drive the UK’s Growth

The UK Research and Innovation (UKRI) and the National Institute for Health and Care Research (NIHR) are the major government funding agencies that provide funding for research on numerous disorders. The NIHR allocated £199,500 for research concerning AS in FY 2023-24. AS affects approximately 200,000 people in the UK, causing severe pain and spinal fusion.

South America's Ascent in AS Treatment

Latin America is rapidly embracing advanced ankylosing spondylitis therapies. The ankylosing spondylitis market is expanding due to improved diagnostic capabilities and a rising patient population. Key players are targeting this region through strategic partnerships to increase the availability of effective, modern treatments for inflammatory diseases. The overall trend is highly positive.

Argentina's Focus on Specialty Care

Argentina is seeing significant growth driven by heightened disease awareness. There is a noticeable shift towards advanced treatment modalities like biologic agents for Ankylosing Spondylitis. Local initiatives are focusing on early diagnosis and management, improving patient outcomes, and stimulating demand within the rheumatology specialty clinics across the country.

MEA's Emerging Healthcare Landscape

The Middle East and Africa region presents lucrative opportunities for AS therapeutics. The ankylosing spondylitis market expansion in MEA is driven by increased investment in healthcare infrastructure and rising awareness of chronic inflammatory diseases. Challenges remain, such as the high cost of biologics, but partnerships are forming to expand patient access to crucial treatment options.

UAE Drives Adoption of Modern AS Drugs

The UAE market for ankylosing spondylitis drugs is experiencing a strong upswing. The increased incidence of the condition and demand for effective treatments are fueling growth. There is an increasing focus on new biologic and small-molecule therapies, particularly through hospital pharmacies, reflecting the nation's high standard of specialized care.

Company Landscape

1. Novartis AG

Company Overview:

• Novartis is a global healthcare leader focused on innovative medicines, generics, and biosimilars, with a strong presence in immunology, oncology, and neuroscience.

Corporate Information:

• Headquarters: Basel, Switzerland
• Year Founded: 1996 (merger of Ciba-Geigy and Sandoz)
• Ownership Type: Public (Aktiengesellschaft)

History and Background:

• Formed by the merger of Ciba-Geigy and Sandoz in 1996 to create a diversified pharma group. The company was later structured into divisions like Innovative Medicines and Sandoz.

Key Milestones/Timeline:

• 1996: Merger of Ciba-Geigy and Sandoz to form Novartis.
• 2015: FDA originally approved Cosentyx (secukinumab) for psoriasis; later expanded.
• 2024: European Commission granted landmark approval for Cosentyx in ankylosing spondylitis.
• 2025: $23 B U.S. investment announced for R&D and manufacturing.

Business Overview:

• Novartis develops, manufactures, and markets a broad range of pharmaceutical products, including patented medicines, generics, and biosimilars.

Business Segments/Divisions:

• Innovative Medicines (pharma and oncology)
• Sandoz (generics & biosimilars)
• Corporate / Holding functions

Geographic Presence:

• Global operations in ~140 countries, with ~78,000 employees.

Key Offerings (in AS):

• Cosentyx (secukinumab), IL-17A inhibitor for ankylosing spondylitis.

End-Use Industries Served:

• Primarily pharmaceutical/healthcare — rheumatology, immunology, inflammation.

Key Developments and Strategic Initiatives:

• U.S. facility expansion: $23 B to build 10 plants, including a research hub in San Diego.
• Collaboration with Schrödinger (computational drug discovery) for next-gen molecules.

Mergers & Acquisitions:

• In 2025, Novartis acquired Anthos Therapeutics (up to $3.1 B) to bolster its cardiovascular pipeline.

Partnerships & Collaborations:

• Multi-year collaboration with Schrödinger valued up to $2.5 B to integrate computational discovery.

Product Launches/Innovations:

• Continued life cycle management of Cosentyx, including IV formulations in other indications.

Capacity Expansions/Investments:

• Major U.S. manufacturing and R&D build-out as part of $23 B plan.

Regulatory Approvals:

• FDA approvals for Cosentyx in ankylosing spondylitis and psoriatic arthritis.
• European Commission approval for AS indication.

Distribution Channel Strategy:

• Novartis distributes globally via a network of subsidiaries, wholesalers, and specialty pharma channels.

Technological Capabilities/R&D Focus:

• Strong focus on biologics, computational discovery, precision medicine, and novel modalities.

Core Technologies/Patents:

• Monoclonal antibodies (IL-17) such as secukinumab.
• Proprietary platforms in computational drug design via Schrödinger collaboration.

Research & Development Infrastructure:

• Multinational R&D centers (e.g., Basel, U.S.)
• Global clinical trial network for immunology indications, including AS.

Innovation Focus Areas:

• Next-gen immunology therapies
• Computational drug discovery
• Biologics and biosimilars

Competitive Positioning:

• Strengths & Differentiators: First mover with IL-17A inhibitor in AS; strong global footprint; deep R&D.
• Market Presence & Ecosystem Role: Major biologics innovator; sets benchmark in IL-17 class.

SWOT Analysis:

• Strengths: Broad global reach; innovation pipeline; deep immunology expertise.
• Weaknesses: High manufacturing costs; patent expiry risk.
• Opportunities: Expand Cosentyx into more markets/indications; computational drug AI.
• Threats: Biosimilar competition; regulatory risk; pricing pressures.

Recent News & Updates:

• 2025: Announced $23 B investment in U.S. manufacturing/R&D.
• 2025: Collaborated with Schrödinger for computational drug discovery.

Press Releases:

• European Commission approval for Cosentyx in AS.
• FDA approval for AS/PsA indications.

Industry Recognitions/Awards:

• Recognized for R&D leadership and innovation in immunology by multiple industry observers (per annual reports).

2. AbbVie Inc.

Company Overview:

• AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and other specialty medicines.

Corporate Information:

• Headquarters: North Chicago, Illinois, USA
• Year Founded: 2013 (spin-off from Abbott Laboratories)
• Ownership Type: Public

History and Background:

• AbbVie was created in 2013 when Abbott Laboratories split its research-based business. It has built a strong immunology franchise around Humira and newer therapies.

Key Milestones/Timeline:

• 2013: AbbVie spun off from Abbott Laboratories.
• 2016–2020s: Humira dominated its revenue, then biosimilar competition grew.
• 2024–2025: Shift toward newer immunology assets – Rinvoq, Skyrizi.

Business Overview:

• AbbVie develops, manufactures, and markets prescription drugs, especially in immunology, oncology, and other specialty areas.

Business Segments/Divisions:

• Immunology
• Oncology
• Neuroscience
• Aesthetics & Women’s Health

Geographic Presence:

• Global presence, with operations in the U.S., Europe, Asia, and emerging markets.

Key Offerings (in AS):

• Humira (adalimumab), a TNF-alpha inhibitor widely used in ankylosing spondylitis.
• End-Use Industries Served:
• Healthcare/Pharmaceuticals, specifically for autoimmune diseases, rheumatology, and chronic inflammatory conditions.

Key Developments and Strategic Initiatives:

• Transitioning focus from Humira to next-gen immunology drugs.
• Negotiated biosimilar strategies and market access adjustments.

Mergers & Acquisitions:

• 2024: Acquired ImmunoGen for US$10.1 B to strengthen oncology pipeline.
• 2024: Bought Cerevel Therapeutics (~US$8.7 B) to boost neuroscience.

Partnerships & Collaborations:

• AbbVie has research collaborations across academia and biotech; its focus is on immunology, neuroscience, and oncology.

Product Launches/Innovations:

• Actively growing newer immunology products like Skyrizi and Rinvoq to reduce dependency on Humira.

Capacity Expansions/Investments:

• AbbVie is investing in manufacturing and pipeline to support next-generation biologics and small molecules.

Regulatory Approvals:

• Humira is approved for ankylosing spondylitis. AbbVie’s newer immunology drugs continue to get regulatory traction.

Distribution Channel Strategy:

• Uses global commercial networks, specialty pharmacies, hospital channels, and reimbursement partnerships.

Technological Capabilities/R&D Focus:

• Strong R&D in antibody engineering, immunology, small molecule drugs, and biosimilars.

Core Technologies/Patents:

• TNF-alpha biologics (Humira)
• Small molecules (JAK inhibitors like Rinvoq)
• IL-23 / IL-17 + novel mechanisms

Research & Development Infrastructure:

• Worldwide clinical trial presence; immunology labs; advanced analytics for biologic development.

Innovation Focus Areas:

• Next-gen immunology (beyond TNF)
• Biologics and small-molecule hybrid therapies
• Precision immune medicine

Competitive Positioning:

• Strengths & Differentiators: Strong legacy (Humira), deep immunology pipeline, global reach.
• Market Presence & Ecosystem Role: Key legacy biologics provider; pivoting to sustainable growth.

SWOT Analysis:

• Strengths: Established brand, broad immunology expertise; strong cash flow.
• Weaknesses: Patent expiry risk on Humira; biosimilar pressure.
• Opportunities: Expand newer drugs (Rinvoq, Skyrizi) into more indications, including AS.
• Threats: Biosimilar competition; regulatory pricing pressure; shifting payer policies.

Recent News & Updates:

• 2025: Q3 earnings beat, driven by Skyrizi (+47%) and Rinvoq (+35%) growth.
• 2024: Cigna announced the removal of Humira from some reimbursement lists in favor of biosimilars.

Press Releases:

• Public communications about immunology pipeline transformation and biosimilar strategy.
• Investor releases on earnings growth driven by newer immunology therapies.

Industry Recognitions/Awards:

• AbbVie is regularly highlighted as a leader in immunology R&D and commercial execution in specialty pharma circles.

Top Companies & Their Offerings in the Ankylosing Spondylitis Market

Other Companies

• AbbVie, Inc.
• Johnson & Johnson
• Gilead Sciences
• Janssen Pharmaceuticals, Inc.
• Suzhou Zelgen Biopharmaceuticals Co., Ltd.
• Amgen, Inc.
• Samsung Biologics
• Fresenius Kabi

Recent Developments in the Ankylosing Spondylitis Market

• In July 2025, Biocon Biologics Ltd. announced the launch of Nepexto, a biosimilar of the reference product Enbrel (Etanercept), in the Australian market. Biocon collaborated with Generic Health to deliver the drug in Australia, broadening patient access to affordable treatment options in the country.
• In April 2025, Biocad, the Russian National Research Medical University of Pirogov, and the Institute of Bioorganic Chemistry developed Seniprutug, a domestic drug for the treatment of AS. The drug will benefit patients from 45 Russian regions, which can relieve symptoms and stop its progression.

Segments Covered in the Report

By Drug Class

• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
• TNF Inhibitors 
  • Adalimumab
  • Infliximab
  • Etanercept
• IL-17 Inhibitors 
  • Secukinumab
  • Ixekizumab
• JAK Inhibitors
• DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
• Analgesics & Corticosteroids
• Emerging Biologic Therapies

By Route of Administration

• Subcutaneous
• Oral
• Intravenous
• Infusion Center-based Delivery

By Disease Stage

• Early-Stage Ankylosing Spondylitis
• Moderate Ankylosing Spondylitis
• Severe / Advanced Ankylosing Spondylitis

By Diagnostic Method

• MRI
• X-Ray Radiography
• Blood Biomarkers (CRP/ESR)
• HLA-B27 Genetic Testing
• Digital Spine Monitoring Tools

By End-User

• Hospitals
• Specialty Rheumatology Clinics
• Diagnostic Imaging Centers
• Ambulatory Care Centers
• Online Pharmacies & Specialty Drug Distributors

By Region

• North America 
  • US
  • Canada
  • Mexico
  • Rest of North America
• South America 
  • Brazil
  • Argentina
  • Rest of South America
• Europe 
  • Western Europe 
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus
    • Turkiye
    • Albania
    • Rest of Eastern Europe
• Asia Pacific (APAC) 
  • China
  • Taiwan
  • India
  • Japan
  • Australia & New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• Middle East and Africa (MEA) 
  • GCC Countries 
    • Saudi Arabia
    • United Arab Emirates (UAE)
    • Qatar
    • Kuwait
    • Oman
    • Bahrain
  • South Africa
  • Egypt
  • Rest of MEA